Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

October 8, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • New Acyl CoA synthetase 4 inhibitor reduces breast and prostate tumour growth

Witnessing rays of hope as the first Ebola treatment wins approval by FDA

Is the pandemic interfering with the treatment for other diseases?

New Acyl CoA synthetase 4 inhibitor reduces breast and prostate tumour growth
  • BiotechToday
  • World

New Acyl CoA synthetase 4 inhibitor reduces breast and prostate tumour growth

bioxone October 19, 2020October 19, 2020

Rohit Bhattacharjee, Amity University Kolkata

Acyl CoA synthetase 4 (ACSL4) is an isoenzyme of the fatty acid ligase-coenzyme A family that takes part in arachidonic acid metabolism and steroidogenesis. ACSL4 is involved in tumour aggressiveness in breast and prostate tumours through various signal transduction pathways regulation. A well-validated ACSL4 inhibitor, however, has not been reported that hinders the entire exploration of the promising target and its therapeutic application on cancer and steroidogenesis inhibition. But in this regard, PRGL493 is identified as a homology model for ACSL4 and docking based virtual screening. Then it was chemically characterized through NMR and mass spectroscopy.

The inhibitory activity was demonstrated through the inhibition of arachidonic acid transformation into arachidonoyl CoA using recombinant enzyme and cellular models. The compound blocked cell proliferation and tumour growth in both breast and prostate cellular and animal models and sensitized the tumour cells to chemotherapeutic and hormonal treatment. Additionally, PRGL493 inhibited de novo steroid synthesis in testis and adrenal cells, in a mouse model and prostate tumour cells. This work proves the concept for potential application of PRGL493 in clinical practice. Moreover, they might prove keys to therapies aiming at control of tumour growth and drug resistance in tumours that express Acyl CoA synthetase 4 (ACSL4) and rely on steroid synthesis.

Also read: Efficient and cost-effective Bacterial mRNA sequencing causing ribosomal RNA depletion

Source- 

Castillo, A.F., Orlando, U.D., Maloberti, P.M. et al. New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumour growth, therapeutic resistance and steroidogenesis. Cell. Mol. Life Sci. (2020). https://doi.org/10.1007/s00018-020-03679-5

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged ACSL4 arachidonic acid breast tumour chemotherapeutics de novo synthesis hormonal treatment inhibitor mass spectroscopy NMR PRGL493 prostate steroidogenesis

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Is the pandemic interfering with the treatment for other diseases?

bioxone October 19, 2020

Camelia Bhattacharyya, Amity University Kolkata The pandemic, that is, the COVID-19 pandemic hit the world all of a sudden, changing infection rates or rather increasing it every day without leaving the world to think of the ways to fight with the unknown enemy, the virus. This created a lot of panic at the beginning of […]

other diseases

Related Post

  • BiotechToday
  • World

Sponges provide insights into nervous system evolution!

BioTech Today December 7, 2021December 7, 2021

Debarati Basu, Makaut WB The brain is the most unique and vital organ of the human body. It is composed of nearly 86 billion neurons that help in communication through synapses. These neurons help in performing various body functions that include vision, movement, understanding, consciousness, and so on. Thus it helps in performing the most […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

CR3022 antibody: fight against SARS-CoV-2

bioxone December 11, 2020December 11, 2020

Parnad Basu, Amity University Kolkata While the whole world is fighting with SARS-CoV-2, scientists are continuously searching for ways to beat the virus. Doing so, they have found out an antibody, CR3022. This CR3022 was able to neutralize the SARS-CoV, which caused an epidemic in 2003. CR3022 had been collected from a patient 14 years […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

mRNA-1273 shows promising results after Phase 3 trial

bioxone November 19, 2020November 19, 2020

Prama Ghosh, Amity University Kolkata An interim review shared by an independent data and safety monitoring board (DSMB) about mRNA-1273 – a COVID-19 vaccine overseeing its Phase 3 trial suggests that the vaccine is safe and effective at preventing symptomatic COVID-19 in adults after its interim analysis with the trial oversight group on Nov. 15, 2020.  […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy